
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion Inc reported a significant improvement in its financial metrics, highlighted by a 320 basis points year-over-year increase in adjusted EBITDA margin and a gross margin of 65.6%, which exceeded estimates by 190 basis points. The company's Preservation Services segment generated $25.7 million, reflecting a 5% growth in the third quarter of 2025, while product sales surged 19%, totaling $87.7 million, driven by strong performances in key categories such as aortic stent grafts and On-X products. Overall, Artivion’s robust product portfolio, ongoing international expansion, and strong revenue growth are expected to foster further margin enhancements, establishing a positive outlook for the company.
Bears say
The financial outlook for Artivion Inc is clouded by several risks that could negatively impact its revenue growth, particularly in relation to the company's reliance on new product approvals and market dynamics. Delays in clinical trials and disappointing sales from new product launches are anticipated to result in slowing revenue growth, with projections estimating mid- to high-single digit increases or lower. Additionally, the company faces significant challenges, including potential tariffs and regulatory changes in international markets that may affect its tissue preservation services revenue, which is a critical component of its overall financial performance.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares